<DOC>
	<DOC>NCT00124930</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.</brief_summary>
	<brief_title>Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer</brief_title>
	<detailed_description>The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>&gt;18 years of age Significant nausea/vomiting Failed maxeran and domperidone Underlying treatment of causes has failed Adequate cognitive function Communicates well Partial/complete bowel obstruction Currently taking Haldol or olanzapine Has drug induced extrapyramidal symptoms Parkinson's disease Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>olanzapine</keyword>
	<keyword>haldol</keyword>
	<keyword>cancer</keyword>
	<keyword>nausea</keyword>
	<keyword>second line treatment</keyword>
	<keyword>refractory nausea</keyword>
</DOC>